99 related articles for article (PubMed ID: 21918903)
1. Evaluation of a formula for individual dosage of nedaplatin based on renal function.
Sato S; Fujiwara H; Oishi T; Shimada M; Machida S; Takei Y; Itamochi H; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Mar; 69(3):599-603. PubMed ID: 21918903
[TBL] [Abstract][Full Text] [Related]
2. A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients.
Ishibashi T; Yano Y; Oguma T
Cancer Chemother Pharmacol; 2002 Sep; 50(3):230-6. PubMed ID: 12203105
[TBL] [Abstract][Full Text] [Related]
3. Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.
Shimada M; Fujiwara H; Sato S; Oishi T; Itamochi H; Machida S; Takei Y; Harada T; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2012 Jul; 70(1):33-8. PubMed ID: 22610355
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis.
Ishibashi T; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1273-81. PubMed ID: 15865078
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of concurrent chemoradiation with weekly nedaplatin in patients with squamous cell carcinoma of the uterine cervix.
Yoshinaga K; Niikura H; Ogawa Y; Nemoto K; Nagase S; Takano T; Ito K; Yaegashi N
Gynecol Oncol; 2007 Jan; 104(1):36-40. PubMed ID: 16889822
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
9. Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion.
Ishibashi T; Fukumura K; Yano Y; Oguma T
Anticancer Res; 2005; 25(2B):1283-9. PubMed ID: 15865079
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study for determination of the dosage formula for intra-arterial infusion chemotherapy with nedaplatin].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 May; 31(5):713-6. PubMed ID: 15170978
[TBL] [Abstract][Full Text] [Related]
11. Chemoradiation therapy using radiotherapy, systemic chemotherapy with 5-fluorouracil and nedaplatin, and intra-arterial infusion using carboplatin for locally advanced head and neck cancer - Phase II study.
Fuwa N; Kodaira T; Furutani K; Tachibana H; Nakamura T; Daimon T
Oral Oncol; 2007 Nov; 43(10):1014-20. PubMed ID: 17258494
[TBL] [Abstract][Full Text] [Related]
12. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin-based combination chemotherapy for testicular cancer: relationship among administration dose of carboplatin, renal function and myelosuppression.
Suzuki K; Matsumoto K; Hashimoto K; Kurokawa K; Jinbo S; Suzuki T; Imai K; Yamanaka H; Kawashima K; Takahashi H
Hinyokika Kiyo; 1995 Oct; 41(10):775-80. PubMed ID: 8533673
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer].
Ohbayashi Y; Miyake M; Iwasaki A; Ogawa T; Nagahata S; Toyama Y; Ohkawa M
Gan To Kagaku Ryoho; 2004 Jan; 31(1):41-4. PubMed ID: 14750319
[TBL] [Abstract][Full Text] [Related]
16. Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats.
Uehara T; Tsuchiya N; Masuda A; Torii M; Nakamura M; Yamate J; Maruyama T
J Appl Toxicol; 2008 Apr; 28(3):388-98. PubMed ID: 17685399
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
